Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech firm Archemix has said that it will receive a $1 million milestone payment from its collaborator Nuvelo. The milestone payment has been triggered by Nuvelo's enrollment of the first volunteer in a Phase I study of NU172, a thrombin-inhibiting aptamer.
Subscribe to our email newsletter
The Phase I proof-of-concept trial is being conducted at a single center with approximately 30 healthy male volunteers and is designed to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172.
Dr. Errol De Souza, president and CEO of Archemix, said: “We are pleased that Nuvelo has advanced NU172 into clinical trials. NU172 demonstrates the productivity of our aptamer discovery efforts and we look forward to its clinical development.”